Effects of Nicotinamide Mononucleotide Supplementation on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Nutrients · 2026
DOI: 10.3390/nu18060890 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Nutrients, 2026. Verfasst von Mu Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutritional and Toxicological Science, School of Public Health and Nursing, Hangzhou Normal University, Hangzhou 311121, China. Hauptthemen laut MEDLINE: Blood Pressure, Dietary Supplements, Nicotinamide Mononucleotide, Hypertension. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientific Research Foundation for Scholars of HZNU.
Abstract (Originalsprache)
Background/Objectives: High blood pressure remains a primary modifiable risk factor for cardiovascular disease. Nicotinamide mononucleotide (NMN) has emerged as a promising supplement; however, its efficacy with respect to blood pressure in humans is unclear. This meta-analysis systematically evaluated the effects of various NMN supplements on resting systolic blood pressure (SBP) and diastolic blood pressure (DBP) in adults with elevated blood pressure.
Methods
A systematic literature search was conducted to identify eligible randomized controlled trials (RCTs) using the databases PubMed/MEDLINE, Scopus, Web of Science, and EBSCO from their inception to 13 December 2025. R software was used to combine the data from the included original trials using a common-effects model. Subgroup analyses were performed based on age, baseline body mass index, geographical location, intervention duration, NMN dosage, and baseline blood pressure.
Results
A total of 349 participants from 10 RCTs with 11 intervention arms were included. Compared with the placebo, NMN supplementation was associated with a statistically significant but modest reduction in resting DBP (WMD, −2.15 mmHg; 95% CI: −3.68 to −0.61). In contrast, the reduction in resting SBP was not statistically significant. Notably, subgroup analyses revealed that NMN supplementation resulted in a significant reduction in SBP specifically among participants aged 60 years and older (WMD: −3.94 mmHg; 95% CI: −7.06 to −0.82).
Conclusions
Our findings provide preliminary and suggestive evidence that NMN supplementation may be associated with a small reduction in resting DBP and a modest beneficial effect on resting SBP in adults aged 60 years and older. However, the potential of NMN as a viable candidate for early-stage blood pressure management requires confirmation through long-term, large-scale, high-quality RCTs in future clinical studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nutritional and Toxicological Science, School of Public Health and Nursing, Hangzhou Normal University, Hangzhou 311121, China.
ORCID-Profile: Chenyang Wu, Yingying Liu, Jun Yang, Shufen Han
Förderung
- Scientific Research Foundation for Scholars of HZNU
Zitieren
APA
Zhang, M., Chen, Y., Jiang, N., Zeng, J., Zhang, J., Wu, C., Liu, Y., Nie, Z., Yang, J., & Han, S. (2026). Effects of Nicotinamide Mononucleotide Supplementation on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients. https://doi.org/10.3390/nu18060890
Vancouver
Zhang M, Chen Y, Jiang N, Zeng J, Zhang J, Wu C, et al. Effects of Nicotinamide Mononucleotide Supplementation on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients. 2026. doi:10.3390/nu18060890
BibTeX
@article{Zhang2026,
author = {Zhang, Mu and Chen, Yingci and Jiang, Nan and Zeng, Jingjing and Zhang, Jianyun and Wu, Chenyang and Liu, Yingying and Nie, Zizheng and Yang, Jun and Han, Shufen},
title = {Effects of Nicotinamide Mononucleotide Supplementation on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials},
journal = {Nutrients},
year = {2026},
doi = {10.3390/nu18060890}
}
EUVIMED